Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban

Unlike vitamin K antagonists (VKAs), the new oral anticoagulants (NOACs)—direct thrombin inhibitor, dabigatran, and direct activated factor X inhibitors, rivaroxaban, and apixaban—do not require routine INR monitoring. Compared to VKAs, they possess relatively rapid onset of action and short halfliv...

Descripción completa

Detalles Bibliográficos
Autores principales: Ru San, Tan, Chan, Mark Yan Yee, Wee Siong, Teo, Kok Foo, Tang, Kheng Siang, Ng, Lee, Sze Huar, Chi Keong, Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444866/
https://www.ncbi.nlm.nih.gov/pubmed/22997573
http://dx.doi.org/10.1155/2012/108983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444866/
https://www.ncbi.nlm.nih.gov/pubmed/22997573
http://dx.doi.org/10.1155/2012/108983

Ejemplares similares